July 2015 Digestive Health

Belsomra

July 10, 2015

Rx Product News Profile

The FDA has approved Merck's Belsomra (suvorexant), a Schedule IV substance, for the treatment of insomnia, as characterized by difficulties with sleep onset and/or sleep maintenance.